Objectives. The objectives of this study were to characterize patients with predominantly axial SpA who received SSZ as their first DMARD, compare the response to treatment in patients with and without peripheral disease and identify predictors of discontinuation of SSZ. We also investigated response to TNF inhibitor (TNFi) after SSZ failure.
Introduction
Prior to the introduction of the TNF-a inhibitors (TNFis), SSZ was one of the few pharmacological options available to patients with AS and axial SpA who had insufficient response to NSAIDs. In the current recommendations for management of AS [1] and the recommendations for the use of TNFis in axial SpA [2], SSZ is listed as an option for the treatment of patients with peripheral involvement but not for those without peripheral involvement [1] . This recommendation in mainly based on the 2005 Cochrane review by Chen et al. [3] , with particular focus on the studies by Clegg et al. [4] and Nissila et al. [5] . In addition to showing effectiveness in patients with peripheral disease, the Cochrane review suggested that patients with shorter disease duration and increased ESR might benefit more from treatment with SSZ. A relatively large study of patients with undifferentiated SpA was published in 2006 and, contrary to previous reports, demonstrated better outcomes in patients without peripheral disease [6] . However, all new publications after the Cochrane review were recently reviewed by van den Berg et al. [7] , and they concluded that the effect on the BASDAI was not superior with SSZ compared with placebo.
The efficacy of treatment with TNFi in AS is well documented [811] , and superiority over SSZ has recently been confirmed in two randomized trials [12, 13] . Data from one of these trials showed that etanercept was also superior to SSZ in patients with peripheral joint swelling [13] . However, TNFi therapy is costly and has known short-term and potential unknown long-term adverse effects. There might therefore still be a role for treatment with SSZ in some patients with axial SpA.
Our objective was to describe the patients who were prescribed SSZ as their first DMARD and to investigate whether responses to SSZ were better in those with peripheral joint swelling at baseline and to investigate predictors of SSZ discontinuation. Finally, we wanted to investigate whether initiation of TNFis was delayed or responses impaired in patients who received SSZ as their first DMARD but later started TNFi treatment.
Methods
Data for the current analyses were provided by the NOR-DMARD study, a longitudinal observational study including patients from five rheumatology departments in Norway with a clinical diagnosis of any inflammatory joint disease starting a new DMARD treatment. The NOR-DMARD study was approved by the Regional Ethics Committee of Eastern Norway and all patients provided written, informed consent before inclusion. The ethical approval included broad consent to analyse the data of the NOR-DMARD study; no additional ethical approval was required to perform the analysis of anonymized patient data that is reported in this study. The data collection included demographics, disease characteristics, previous treatments (at baseline), a number of patient-reported outcome measures, physician global assessment, 32-joint count (standard 28 joints plus ankles and combined metatarsophalangeal joints) and acute phase reactants (baseline and follow-up visits). The BASDAI and BASFI were only included from 2006 onwards. Followup visits took place at 3, 6 and 12 months and annually thereafter as long as treatment was continued. Patients were not assessed between treatments, but were included whenever they started a new treatment. Adverse events were recorded at all follow-up visits. Patients included in these analyses were recruited from January 2001 to May 2012, had a diagnosis of predominantly axial SpA [International Classification of Diseases, 10th revision (ICD-10) codes: M45, M46.1, M46.8 or M46.9], were DMARD naive and were started on either SSZ or a TNFi. Among the patients who started on SSZ, we further identified patients who later switched to a TNFi.
Baseline characteristics, including disease activity measures, were compared between patients starting SSZ or TNFi as their first DMARD. Comparisons at baseline were also performed between those starting a TNFi after failing SSZ and those who received a TNFi as their first DMARD. Selected measures of disease activity were joint counts, CRP, ESR, patient and physician global assessment of disease activity, the modified HAQ (MHAQ) [14] , the Short-Form 6-Dimensions (SF-6D) utility measure [15] , Ankylosing Spondylitis Disease Activity Score (ASDAS) [16] , BASDAI [17] [including individual items 2 (back pain score) and 3 (peripheral symptoms)] and BASFI [18] .
Three-month responses to SSZ were compared between patients with and without swollen joints at baseline and were assessed by changes from baseline in patient and physician global assessments, MHAQ, SF-6D, ASDAS, BASDAI, BASFI, CRP and joint counts, and by ASDAS, BASDAI and the Assessment of SpondyloArthritis International Society (ASAS) responses. Outcomes based on BASDAI (including ASDAS and ASAS responses) were incomplete due to late inclusion of BASDAI in the data collection (from 2006). ASAS responses were calculated using the BASDAI back pain score, as a separate question on spinal pain was not part of the data collection. As sensitivity analyses, nonresponder imputation was applied at 3 and 6 months and a 6-month completer analysis was performed. Threemonth responses to TNFi with the same outcome measures were compared between TNFi-naive patients and those who had previously used SSZ. Statistical comparisons were performed by independent t-test for continuous measures, except for variables with skewed distributions (CRP and joint counts), for which the MannWhitney U-test was used. For categorical measures, the chisquare test was used, but was substituted by Fisher's exact test when more than five patients had a predicted outcome. Adjusted analyses were performed by analysis of covariance (ANCOVA) (continuous variables) and logistic regression (categorical variables).
Simple comparisons of drug survival were performed using KaplanMeier analysis with the log-rank test, and a Cox regression analysis was applied to identify predictors of SSZ discontinuation (all causes). We also performed KaplanMeier analyses comparing discontinuations overall and discontinuations due to adverse events in patients treated with SSZ vs patients treated with a TNFi as their first DMARD.
For the Cox regression analysis, potential predictors were tested by univariate analysis and those with a P-value <0.25 were included in the multivariate analysis. All variables with a P-value <0.10 were kept in the final multivariate model; gender and age were kept in the model regardless of statistical significance. SPSS version 20 (IBM, Armonk, NY, USA) was used for all statistical analyses.
Results
We included 181 patients starting SSZ as their first DMARD, and among these we identified 66 patients who later switched to a TNFi. We also included 543 patients starting a TNFi as their first DMARD. While the number of patients included with SSZ as their first DMARD was quite stable over the inclusion period, there was a large increase in the number of patients included receiving a TNFi as their first DMARD (supplementary Fig. S1 , available at Rheumatology online). Of the patients included, 89.5% had a diagnosis of AS (ICD-10 code M45) (81.8% of SSZ-treated patients and 92.1% of DMARD-naive TNFi-treated patients).
Baseline characteristics for the different groups are presented in Table 1 . Patients who received SSZ as their first DMARD were less frequently male, had shorter disease duration, more swollen joints and lower physician global assessment than those who received a TNFi. Disease activity measures were otherwise similar, except for BASDAI question 3 regarding peripheral disease.
Patients who later switched from SSZ to a TNFi had a slightly lower HLA-B27 prevalence, fewer swollen joints and slightly higher disease activity than the overall group of patients receiving SSZ. When the TNFi was initiated, these patients had a similar disease duration and disease activity (except slightly higher joint counts) compared with those who initiated a TNFi as their first DMARD ( Table 1) . The proportion of patients receiving each of the available TNFis was quite similar between the switchers and the DMARD-naive patients: etanercept, 56.1/47.1%; infliximab, 12.1/16.0%; adalimumab, 22.7/26.0%; golimumab, 9.1/10.7% and certolizumab pegol, 0.0/0.2%, respectively. Concomitant DMARDs were used in 7.2% of DMARD-naive patients and 16.7% of switchers; in both groups this was more commonly MTX than SSZ.
Responses to SSZ are shown in Table 2 . Responses to SSZ were numerically slightly better in patients who had swollen joints at baseline, but statistically significant differences were only observed for patient global assessments and BASDAI. There were baseline differences between the groups (supplementary Table S1 , available at Rheumatology online), but efficacy analyses with adjustment for age and ASDAS yielded similar results ( Table 2 ). The number of swollen joints decreased during the first 3 months in the group with swollen joints at baseline {median 2 [interquartile range (IQR) 14] vs 1 (IQR 03.5), P = 0.002 (Wilcoxon signed rank test)]. Six-month responses and non-responder imputation analysis for dichotomous outcomes did not show consistent statistically significant differences between patients with and without swollen joints (supplementary Table S3 , available at Rheumatology online).
Three-year drug survival was significantly better in patients with vs without swollen joints at baseline (0.22 vs 0.10, P = 0.03) (Fig. 1A) . The overall estimated 3-year drug survival rate was 0.16 ( Fig. 1A) . We identified the absence of joint swelling at baseline, increasing CRP and increasing BASDAI back pain score as predictors of discontinuation of SSZ (Table 3) . Responses to TNFis are shown in Table 4 . Responses were similar between patients who had previously used SSZ and those who were DMARD naive, also when adjusting for baseline differences. The 3-year drug survival was also similar between groups (0.57 vs 0.53; Fig. 1B ). There was no clear indication of better response or drug survival in patients with swollen joints in DMARD-naive patients starting a TNFi (supplementary Table S2 and Fig. S2 , available at Rheumatology online).
Adverse events (AEs) were recorded as a cause of discontinuation in 42.6% (n = 58) of patients who had received SSZ, and was more commonly reported than inefficacy (37.5%). The most common AEs at discontinuation were gastrointestinal discomfort (46.6%), skin reactions (19.0%), headache/dizziness (19.0%) and fatigue (12.6%), and several patients reported more than one AE at discontinuation. Retrospectively we classified 22.4% (n = 13) of these AEs to be serious, including elevated transaminases (n = 4), allergic reactions (n = 2), neutropenia (n = 2), dyspnoea (n = 1), anaemia (n = 1), atrial fibrillation (n = 1) and stroke (n = 1, regarded as unrelated to medication). Slightly more patients discontinued due to inefficacy among patients without vs with swollen joints (42.0% vs 30.6%), but discontinuations due to AEs were similar (40.6% vs 38.9%). Serious AEs were more numerous in patients with swollen joints (9.4% vs 4.9%), but this difference was not statistically significant (P = 0.37). In comparison, 27.1% of patients starting a TNFi as their first DMARD discontinued due to AEs. When considering discontinuations due to AEs only, patients starting SSZ had significantly poorer drug survival than patients starting a TNFi (supplementary Fig. S3 , available at Rheumatology online).
Discussion
In this study we investigated the baseline characteristics and responses of patients with axial SpA receiving SSZ or a TNFi as their first DMARD. These are by far the most commonly prescribed first DMARDs in our study in patients with axial SpA (only 40 patients received other conventional DMARDs or combinations of conventional DMARDs and were not included). Responses to SSZ were modest and drug survival was poor. We observed a trend towards slightly better 3-month responses in patients with peripheral joint swelling, and they did have superior 3-year drug survival. The absence of joint swelling, higher CRP and a high BASDAI back pain score were identified as independent predictors of discontinuation of SSZ. We could not identify a delay in the initiation of TNFis in those who were first prescribed SSZ, as disease duration and activity when starting TNFis were similar to those who received a TNFi as their first DMARD. Reassuringly, we also found similar responses to TNFis in those previously treated with SSZ compared with those who received a TNFi as their first DMARD.
Patients in this study had a clinical diagnosis of axial SpA, including 10.5% of patients who did not have a clinical diagnosis of AS. The clinical diagnoses of the latter group of patients (ICD-10 codes M46.1, M46.8 and M46.9) do not formally exclude patients with only peripheral SpA, but in our experience, other ICD codes have been used for those patients. As we lacked information about X-ray abnormalities, MRI findings and some SpA features, it is not known how many patients formally fulfilled the ASAS axial SpA criteria and the modified New York criteria, which of course is a limitation of our study. We could have included only AS patients, as data supporting current recommendations are based on this patient group [1] . However, the most current recommendations for the use of TNFis [2] not only applies to AS, but also to non-radiographic axial SpA, including the recommendations regarding the use of SSZ prior to starting a TNFi. It is also worth noting that access to MRI has been good in Norway for many years, and to a large extent it has replaced X-rays as the radiological test of choice in diagnosing axial SpA. In our clinical experience, it is likely that a large proportion of patients in this cohort will have had relevant MRI changes, and that patients may have been given a clinical diagnosis of AS based on typical MRI abnormalities alone. We therefore decided to include all axial SpA patients, not only those with a clinical diagnosis of AS, to obtain the most generalizable results.
Our patient population included a wider diagnostic spectrum than AS, which is relevant because SSZ has been shown to have efficacy in AS, but has not proved www.rheumatology.oxfordjournals.org efficacious in non-radiographic SpA [6] . This off-label use of SSZ in a minority of the patients has to be taken into account in the interpretation of our results. Apart from this, however, our population does not have particular features associated with a poorer response. Disease duration in our population was similar to the study by Nissila et al. [5] , and the mean baseline ESR level (25 mm/h) was similar to other populations in which SSZ has been studied [3] . The difference in disease duration and peripheral joint swelling in patients receiving SSZ vs TNFi as their first DMARD (Table 1 ) might reflect clinical implementation of the conclusions from the Cochrane review that SSZ is efficacious in patients with shorter disease duration and peripheral joint swelling [3] . The proportion of patients with and without swollen joints at baseline starting SSZ was stable over the inclusion period in our study (data not shown). SSZ might have been preferred over TNFi in younger women due to pregnancy planning, which could contribute to age and gender differences between patients starting SSZ vs TNFi as their first DMARD. The slightly lower proportion of patients with a clinical diagnosis of AS might also contribute, as it is well described that the male:female ratio in axial SpA, in contrast to the AS subgroup, is closer to 1:1 [19] .
The observed overall response to SSZ is low, but in patients with swollen joints it is similar to previous reports [3, 6] . It is, however, also similar to the placebo responses to TNFi in the ASSERT trial (for AS) [20] and the ABILITY-1 trial (for axial SpA) [21] . As there is no control group in observational studies like the NOR-DMARD, we cannot exclude the effects of regression towards the mean or a placebo-like effect, both of which are especially relevant when responses are as low as in our study. However, if the response to SSZ in patients with swollen joints was purely due to a placebo-like effect and/or regression towards the mean, we would not expect it to be numerically so consistently higher than responses in patients without swollen joints. The efficacy of SSZ on joint swelling alone is difficult to assess. The change in swollen joint count from baseline to 3 months was significant, but there is no comparator group, and we expect some regression towards the mean. There is some evidence that SpA patients with peripheral arthritis have a more general superior efficacy to treatment since this superiority has also been observed in patients treated with TNFi [22] . However, the response to TNFi in our study was similar in patients with and without peripheral arthritis.
We found that discontinuations due to AEs were more common in patients starting SSZ compared with those who started a TNFi. However, the majority of AEs experienced with SSZ were relatively mild, and it is likely that the poorer efficacy of SSZ compared with TNFi greatly influenced the rates of discontinuation due to AEs. It is still worth taking into account that a significant proportion of patients who start SSZ will experience discomfort related to the treatment, and there is a risk of serious AEs.
As inclusions in this study span from 2001 to 2012, there have of course been major changes in prescription However, prescription rates for SSZ were quite stable and the baseline disease activity at initiating treatment has decreased quite steadily in a similar fashion to TNFis (supplementary Fig.  S4 , available at Rheumatology online). Overall, we found that changes in prescription patterns have been gradual, and that a cut-off for licensing in 2003 would not alleviate this. Regardless of time trends, confounding by indication is always a major issue in analyses from observational studies, and caution must be applied when interpreting the results.
All of the analyses presented on data based on the BASDAI (BASDAI, ASDAS, ASAS responses) as well as the Cox regression analysis (due to inclusion of the BASDAI back pain score as a variable) only included data from 2006 onwards, and the reduced sample size in these analyses needs to be kept in mind when interpreting the results. We have, however, included the full population in the generic outcomes and drug survival analyses. This was done to preserve the power in these analyses. Also, some of the switchers might not have BASDAI data for their SSZ inclusion, but had BASDAI data for the subsequent TNFi treatment. Radiological examinations (X-ray and MRI) would have contributed greatly both to classification and exploring treatment responses, but were, as mentioned, not part of the data collection.
We selected the 3-month visit for our primary response analysis, mainly because the drug survival of SSZ was so poor. At this selected time point, the completer analysis approach was the natural choice, as carrying forward disease activity measures from baseline would be very conservative. It may be argued that 3 months is an insufficient time to see the full effects of SSZ, which is of course a weakness in this approach. The 6-month completer analysis (supplementary Table S3 , available at Rheumatology online) did show higher responses than at 3 months, but this is to be expected since the completer approach is biased towards patients with a more favourable outcome. In the non-responder imputation analyses, however, the responses at 3 and 6 months were quite similar (supplementary Table S3 , available at Rheumatology online).
Our data do not strengthen the position of SSZ as an efficacious treatment for axial SpA, as observed responses to SSZ in patients with peripheral joint swelling were modest and poor responses were found in patients with no joint swelling. The finding that axial disease (BASDAI back pain score) is a predictor of discontinuation of SSZ independent of joint swelling indicates SSZ is not a good option for patients with severe axial disease, regardless of peripheral involvement. The observed AEs were mild in the vast majority of patients, and some might argue that a trial of SSZ in all patients is sound practice, both due to the potentially serious AEs associated with TNFis and from an economic perspective, especially as the use of SSZ does not seem to impair later response to TNFis.
Overall, our findings support the current treatment recommendations for AS and axial SpA in that SSZ is an option for initial DMARD treatment in axial SpA patients with peripheral joint swelling [1, 2], but possibly not for patients who also have severe axial disease. If, however, SSZ is chosen as their first DMARD, our findings are reassuring regarding TNFi efficacy in case of a subsequent switch to a TNFi.
Rheumatology key messages
. The effectiveness of SSZ was modest in axial SpA, especially in patients with no joint swelling. . The response to TNF inhibitors was not impaired in axial SpA patients previously treated with SSZ.
